Loading...
Lumos Pharma, Inc.
LUMO•NASDAQ
Healthcare
Biotechnology
$4.34
$0.00(0.00%)
Lumos Pharma, Inc. (LUMO) Company Profile & Overview
Explore Lumos Pharma, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Lumos Pharma, Inc. (LUMO) Company Profile & Overview
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
SectorHealthcare
IndustryBiotechnology
CEOMr. Richard J. Hawkins
Contact Information
Company Facts
30 Employees
IPO DateNov 11, 2011
CountryUS